O-Coumaric Acid

O-Coumaric Acid

SCHEMBL892006

O=C(O)/C=C\c1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 1.00
CA1 P00915 1/20 1.00
CA2 P00918 1/20 1.00
CA4 P22748 1/20 1.00
JUN P05412 1/20 0.73
NFE2L2 Q16236 1/20 0.73
MAPT P10636 4/20 0.68
LMNA P02545 1/20 0.68
BCHE P06276 1/20 0.63
GUSB P08236 1/20 0.63
CHRNA7 P36544 3/20 0.58
TRPA1 O75762 1/20 0.57
MAPK1 P28482 2/20 0.56
HDAC3 O15379 1/20 0.56
TNKS O95271 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HCAR2 Q8TDS4 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
O-Coumaric Acid SCHEMBL64885 1.00 NFKB1 (1.00) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL64886 1.00 NFKB1 (1.00) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL29353381 1.00 NFKB1 (1.00) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL29367602 1.00 NFKB1 (1.00) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL29368085 1.00 NFKB1 (1.00) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL1221495 0.98 NFKB1 (0.96) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL8719132 0.98 NFKB1 (0.96) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL8719129 0.98 NFKB1 (0.96) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL28048519 0.98 NFKB1 (0.96) NFKB1CA1CA2CA4JUN
O-Coumaric Acid SCHEMBL28048517 0.98 NFKB1 (0.96) NFKB1CA1CA2CA4JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US claimed
US-20220026398-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2022-01-27 US claimed
US-20130155361-A1 DISPLAY PANEL AND MANUFACTURING METHOD THEREOF AND IMAGE DISPLAY SYSTEM CHIMEI INNOLUX CORPORATION (TW) 2013-06-20 US claimed
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP disclosed
WO-2026087745-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-30 WO disclosed
EP-4732825-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-29 EP disclosed
US-20260101892-A1 METHOD TO INHIBIT PROLIFERATION OF A PHYTOPATHOGEN ON PLANTS AND COMPOSITIONS USED FOR THIS PURPOSE CYSBIO APS (DK) 2026-04-16 US disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US disclosed
CN-113773309-B Coumarin pyridinium compound and application thereof 华东理工大学 2024-07-09 CN disclosed
CN-118044994-A Application of hydroxy cinnamic acid, isoamyl acetate or betaine in preparation of composition 株式会社LG生活健康 2024-05-17 CN disclosed
CN-112004516-B Composition for improving skin barrier dysfunction 株式会社LG生活健康 2024-03-12 CN disclosed
US-20090124688-A1 Prostaglandin reductase inhibitors ABGENOMICS CORPORATION (TW) 2009-05-14 US disclosed
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. (US) 2007-09-13 US disclosed
WO-2007082178-A2 PROSTAGLANDIN REDUCTASE INHIBITORS ABGENOMICS CORPORATION (TW) 2007-07-19 WO disclosed
US-20060150283-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-07-06 US disclosed
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-03-02 US disclosed
US-4691040-A ANTIHISTAMINES, ANTIALLERGENS, HALIDES, SULFONATES, PYRROLIDINE HOFFMANN-LA ROCHE INC. (US) 1987-09-01 US disclosed
US-4681954-A 7,8,9,10-tetrahydro-6-oxo-6H-dibenzo(b,d)pyranyloxy-propanes PENNWALT CORPORATION (US) 1987-07-21 US disclosed
EP-0221293-A1 7,8,9,10-Tetrahydro-6-oxo-6H-dibenzo[b,d]pyranyloxy-propanes PENNWALT CORPORATION (US) 1987-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260101892-A1 METHOD TO INHIBIT PROLIFERATION OF A PHYTOPATHOGEN ON PLANTS AND COMPOSITIONS USED FOR THIS PURPOSE HAAO, NOTUM, WEE1 NFKB1 1543/4885CA1 776/4885CA2 1323/4885
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 NFKB1 3784/4885CA1 3891/4885CA2 3833/4885
US-20090124688-A1 Prostaglandin reductase inhibitors PTGIR, PTGDR, PTGDR2 NFKB1 1400/4885CA1 4565/4885CA2 3030/4885
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 NFKB1 3784/4885CA1 3891/4885CA2 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.